retatrutide phase 2 nejm 2023 obesity trial results study sees significant weight loss in drug study Triple hormone receptor agonist retatrutide

10.2337/dc11-s227 76

a direct causal link in humans has not been established, but patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should avoid this class of medicine [16] [17] Gallbladder disease rapid weight loss can increase the risk of gallstones and gallbladder inflammation [25] [26] Diabetic retinopathy rapid improvement in glycaemic control has been associated with worsening of diabetic retinopathy in people with pre-existing disease

This personalized approach complements standard clinical assessment and allows your PlexusDx provider to flag any genetic risk factors that might warrant additional monitoring or alternative therapy

This negative feedback loop forms part of the GH-IGF-1 axis

see ESM)